ANY | Jotup

Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders

Retrieved on:

Friday, December 1, 2023

Certificate, Sale, Liquidation, File, ANY, Person, Proxy, Therapy, Special, Name, Track, Annual report

BOULDER, Colo., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today that its special meeting of stockholders (the “Special Meeting”), which was previously adjourned on November 16, 2023, has been adjourned for a second time to Friday, December 15, 2023 at 10 a.m. Mountain Time with respect to both proposals described in Fresh Tracks’ definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 20, 2023 (the “Proxy Statement”).

Key Points:

In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on October 17, 2023.
During the current adjournment, Fresh Tracks continues to solicit votes from its stockholders with respect to both proposals set forth in the Proxy Statement.
Proxies previously submitted with respect to the Special Meeting will be voted on both proposals at the reconvened Special Meeting as indicated therein, unless properly revoked, and stockholders who have previously submitted a proxy need not take any action.
If Fresh Tracks’ stockholders do not approve Proposal 1, Fresh Tracks intends to seek judicial dissolution, which is likely to be costly and time-consuming and would reduce the amount of cash distributable to Fresh Tracks’ stockholders associated with the Company’s dissolution.

Prospector Capital Corp. Announces New Record and Distribution Date for Issuance of Dividend Shares

Retrieved on:

Wednesday, December 20, 2023

Banking, Professional Services, Finance, Failure, Risk, Superior court, Business analyst, Business, Terrorism, ANY, Person, Register, COVID-19, Distribution, Nature, Annual report, Security (finance)

Prospector today announced that its board of directors has set a new record date for the Prospector Class A Shares as well as for the Prospector Units for the issuance of the Dividend Shares of December 21, 2023, the currently anticipated Closing Date, immediately after giving effect to (i) the redemption of Prospector Class A Shares previously submitted for redemption and (ii) the conversion of each Class B ordinary share of Prospector into 0.75 Prospector Class A Shares and 0.25 Prospector Sponsor Non-Voting Special Shares, a new class of shares in the capital of Prospector convertible into Prospector Class A Shares, on the same date (the “Record and Distribution Date”).

Key Points:

Prospector today announced that its board of directors has set a new record date for the Prospector Class A Shares as well as for the Prospector Units for the issuance of the Dividend Shares of December 21, 2023, the currently anticipated Closing Date, immediately after giving effect to (i) the redemption of Prospector Class A Shares previously submitted for redemption and (ii) the conversion of each Class B ordinary share of Prospector into 0.75 Prospector Class A Shares and 0.25 Prospector Sponsor Non-Voting Special Shares, a new class of shares in the capital of Prospector convertible into Prospector Class A Shares, on the same date (the “Record and Distribution Date”).
The issuance of the Dividend Shares is subject to the consummation of the Business Combination on the same date.
If the Business Combination is not consummated on December 21, 2023, the record date will automatically change to be on such later date on which the Business Combination is consummated, at the time described above.
Neither Prospector nor LeddarTech can give any assurance that the conditions to the Business Combination will be satisfied.

Bancorp 34, Inc. Reports Revised 3rd Quarter Performance, Amends Merger Agreement with CBOA Financial, Inc.

Retrieved on:

Friday, December 22, 2023

Bank, Sale, Form, ANY, Bank statement, CBOA, OTCQB, Prospectus, The Company, AS, Communication, Security (finance)

The reserve for the troubled credit was deemed necessary as the Company progressed through the legal channels required to manage the credit effectively.

Key Points:

The reserve for the troubled credit was deemed necessary as the Company progressed through the legal channels required to manage the credit effectively.
The parties also agreed to extend the outside closing date of the merger to June 28, 2024.
Both the Company and CBOA anticipate seeking shareholder approval of the merger, and the merger becoming effective, in the 1st quarter of 2024.
This communication is being made in respect of the proposed merger transaction between the Company and CBOA.

Inside information: Citycon Oyj successfully completes directed share issue in exchange for repurchasing certain of its hybrid bonds for EUR 6.4 million

Retrieved on:

Wednesday, December 20, 2023

ITS, Finnish Trade Register, Share (finance), Health, NOT, ANY, Transaction, S&P Global Ratings, Citycon, Heart, Annual, EUR, PEOPLE, Standard, Security (finance)

HELSINKI, Dec. 20, 2023 /PRNewswire/ -- The Board of Directors of Citycon Oyj ("Citycon" or the "Company") has decided, by virtue of the authorization granted by the Annual General Meeting of the Company on 21 March 2023, to issue up to 1,210,866 new shares in the Company (the "Shares") to certain institutional hybrid bond holders in the Company (the "Investors") in deviation of the pre-emptive subscription rights of the shareholders (the "Share Issue") in exchange for the Company repurchasing certain of its outstanding subordinated fixed to reset rate 5.25 year non-call undated green capital securities, issued on 22 November 2019 (ISIN XS2079413527, the "2024 Hybrid Bonds") from the Investors in an approximate aggregate principal amount of EUR 7.6 million (the bond repurchases and the Share Issue together, the "Transaction"). Pursuant to the Transaction, the subscription price for the Shares payable by the Investors to the Company is set off against the repurchase price for the 2024 Hybrid Bonds payable by the Company to the Investors.

Key Points:

The Board of Directors has approved the terms and conditions of the Share Issue and the subscription made in accordance with the terms and conditions of the Share Issue.
A total of 1,210,866 Shares were subscribed for in the Share Issue.
The subscription price was EUR 5.30 per Share, and the aggregate subscription price for all Shares was approximately EUR 6.4 million.
The closing price of the Company's share in Nasdaq Helsinki on 19 December 2023 was EUR 5.26.

Fuller, Smith & Turner PLC: Share Buyback Programme

Retrieved on:

Monday, December 25, 2023

London Stock Exchange, Listing Rules, ANY, Annual, Common stock, LAWS, Financial result, Security (finance)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

Key Points:

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
This is consistent with the Company’s capital allocation framework and reflects the Board’s view that the current share price continues to represent a significant discount to the Company’s underlying net asset value.
The Programme is expected to enhance earnings per share.
Any market purchase of ‘A’ Ordinary Shares under the Programme will be announced no later than 7:30 a.m. on the business day following the day on which the purchase occurred.

Publication of the Prospectus and Circular

Retrieved on:

Monday, December 25, 2023

LSE, Bank Holding Company Act, Mass meeting, BANK, Prospectus, A4200 road, London Stock Exchange, Annual general meeting, Official List, ANY, METRO, FCA, Proxy, Cryptocurrency

Metro Bank Holdings PLC (LSE: MTRO LN)

Key Points:

Metro Bank Holdings PLC (LSE: MTRO LN)
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
The Prospectus contains a Notice of General Meeting, which will be held at One Southampton Row, London WC1B 5HA on 27 November at 11.30am.
The Prospectus has been approved by the FCA and, together with a form of proxy relating to voting at the General Meeting, is available on the Company’s website at: www.metrobankonline.co.uk/investor-relations .
Terms used in this announcement shall, unless the context otherwise requires, be as defined in the Prospectus.

Results of PrimaryBid Offer

Retrieved on:

Thursday, December 21, 2023

Molten Ventures plc (LON: GROW, Euronext Dublin: GRW) announced on 27 November 2023 the launch of a fundraise comprising a placing (the "Placing") and subscription (the "Subscription") in conjunction with an offer via PrimaryBid (the "PrimaryBid Offer") (together the "Fundraise") alongside an Offer for Subscription (together with the Fundraise, the "Issue").

Key Points:

Molten Ventures plc (LON: GROW, Euronext Dublin: GRW) announced on 27 November 2023 the launch of a fundraise comprising a placing (the "Placing") and subscription (the "Subscription") in conjunction with an offer via PrimaryBid (the "PrimaryBid Offer") (together the "Fundraise") alongside an Offer for Subscription (together with the Fundraise, the "Issue").
The Company is pleased to announce that the PrimaryBid Offer successfully completed and closed at 3.00 p.m. yesterday.
A total of 888,888 New Ordinary Shares have been subscribed for at a price of 270 pence per New Ordinary Share (the "Issue Price") pursuant to the PrimaryBid Offer.
Following the successful closing of the PrimaryBid Offer, the Company has raised gross proceeds of £57.4 million via the Fundraise.

Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders

Retrieved on:

Friday, November 17, 2023

Sale, Liquidation, Therapy, Annual report, ANY, 2015 Michigan Proposal 1, Proxy, Special, Person, File, Track, Certificate, Name, Security (finance), Auction, Dissolution, Fresh

BOULDER, Colo., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, November 30, 2023 at 10 a.m. Mountain Time with respect to both proposals described in Fresh Tracks’ definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 20, 2023 (the “Proxy Statement”).

Key Points:

In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on October 17, 2023.
During the current adjournment, Fresh Tracks continues to solicit votes from its stockholders with respect to both proposals set forth in the Proxy Statement.
Proxies previously submitted with respect to the Special Meeting will be voted on both proposals at the reconvened Special Meeting as indicated therein, unless properly revoked, and stockholders who have previously submitted a proxy need not take any action.
If Fresh Tracks’ stockholders do not approve Proposal 1, Fresh Tracks intends to seek judicial dissolution, which is likely to be costly and time-consuming and would reduce the amount of cash distributable to Fresh Tracks’ stockholders associated with the Company’s dissolution.

IDEX Biometrics ASA: Private placement of NOK 35 million successfully placed 15 Nov 2023

Retrieved on:

Wednesday, November 15, 2023

Offer, IDEX Biometrics, Private placement, NOT, Oslo Stock Exchange, Convertible bond, Limited company, Security (finance), Risk, ANY, NOK, OTC Bulletin Board, Prospectus, IDEX, FOR, ISIN, Private

Reference is made to the press release from IDEX Biometrics ASA ("IDEX" or the "Company") published earlier today, 15 November 2023, regarding a contemplated private placement of new shares to raise gross proceeds of up to NOK 35 million (the "Private Placement").

Key Points:

Reference is made to the press release from IDEX Biometrics ASA ("IDEX" or the "Company") published earlier today, 15 November 2023, regarding a contemplated private placement of new shares to raise gross proceeds of up to NOK 35 million (the "Private Placement").
The Private Placement has been successfully placed and will raise gross proceeds to the Company of NOK 35 million, through the issue of 78,651,685 new shares (the "Offer Shares") at a price of NOK 0.4450 per Offer Share (the "Offer Price").
Due to the final number of Offer Shares placed, the announced potential second tranche of the Private Placement is cancelled.
The following primary insiders have subscribed for and been allocated Offer Shares in the Private Placement, ISIN NO0003070609, at the Offer Price, NOK 0.4450 per share:

IDEX Biometrics ASA - Contemplated Private Placement

Retrieved on:

Wednesday, November 15, 2023

IDEX Biometrics ASA (the "Company"), a leading provider of advanced fingerprint identification and authentications solutions, has retained Arctic Securities AS as sole manager and bookrunner (the "Manager") to advise on and effect a private placement (the "Private Placement") of new shares in the Company (the "Offer Shares") to raise gross proceeds of up to NOK 35 million.

Key Points:

IDEX Biometrics ASA (the "Company"), a leading provider of advanced fingerprint identification and authentications solutions, has retained Arctic Securities AS as sole manager and bookrunner (the "Manager") to advise on and effect a private placement (the "Private Placement") of new shares in the Company (the "Offer Shares") to raise gross proceeds of up to NOK 35 million.
With such cost reductions and the combined proceeds from the contemplated Private Placement and Convertible Bond, the Company expects to be fully funded through 2024.
The subscription price per Offer Share in the Private Placement (the "Offer Price") and the number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of the Company (the "Board") following an accelerated bookbuilding process.
A private placement enables the Company to raise capital in an efficient manner, and the Private Placement is structured to ensure that a market-based subscription price is achieved.